Product details
MOTS-c is a 16-amino-acid mitochondrial-derived peptide (sequence MRWQEMGYIFYPRKLR) encoded within the 12S ribosomal RNA region of the human mitochondrial genome. It is one of the better-characterized members of the emerging field of mitochondrial-derived peptides (MDPs), which represent a novel class of small peptides translated from short open reading frames within mitochondrial rRNAs. MOTS-c signals through AMPK-pathway activation and has been studied for effects on insulin sensitivity, exercise capacity, glucose metabolism, weight regulation, and age-related mitochondrial dysfunction, making it one of the most translationally promising peptides in the mitochondrial-research category.
Peptuno supplies MOTS-c acetate as a lyophilized powder at ≥99.0% HPLC purity. The analytical packet covers peak-integration HPLC, mass spec confirming the ~2174.6 Da theoretical mass, water content, and counter-ion. Sequence verification by LC-MS/MS is available on request. The molecule's relatively short half-life in plasma (minutes to low hours) makes it a research tool for acute mitochondrial-signaling studies rather than chronic-elevation work, protocols typically use repeated dosing or sustained-release formulations to maintain biological exposure. Four standard fill sizes (10-40 mg) accommodate both routine research aliquot work and extended-research dispensing scales.
Regulatory note: Peptuno supplies MOTS-c strictly for Research Use Only; buyers are responsible for verifying ingredient eligibility in their destination market.
FAQ
- What makes MOTS-c interesting as a mitochondrial-derived peptide?
- MOTS-c was one of the first mitochondrial-derived peptides (MDPs) identified, a class of small peptides translated from short open reading frames within mitochondrial ribosomal RNA. The discovery upended the conventional view that mitochondrial DNA encodes only 13 protein products (subunits of the OXPHOS complexes), revealing a second tier of nucleus-targeted signaling peptides emerging from mitochondrial transcripts. MOTS-c specifically acts retrograde from mitochondria to nucleus, activating AMPK-pathway signaling and modulating nuclear gene expression in response to metabolic stress. The mechanism is mechanistically distinct from most other peptide therapeutics in the longevity / metabolism space.
- How is MOTS-c different from SS-31 (Elamipretide) within the mitochondrial category?
- Both are research peptides relevant to mitochondrial biology, but they act through completely different mechanisms. MOTS-c is an endogenously-encoded peptide that signals retrograde from mitochondria to nucleus through AMPK and related metabolic-sensor pathways, its activity is essentially signaling and gene-expression modulation. SS-31 (Elamipretide) is a synthetic mitochondria-targeted peptide that accumulates in the inner mitochondrial membrane and protects cardiolipin from peroxidation, its activity is direct biochemical protection of OXPHOS machinery. Buyers selecting between them should match the mechanism to the experimental question: metabolic signaling research favors MOTS-c; oxidative-stress and OXPHOS-integrity research favors SS-31.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.